Our Technology
ChallengeLimits of current cancer treatments
Current cancer therapies, including chemotherapy and immunotherapy, face major challenges such as systemic toxicity, limited tumor specificity, and treatment resistance. Many anticancer drugs cause severe side effects by indiscriminately targeting healthy tissues, while some tumors evade immune detection through adaptive mechanisms. Additionally, the immunosuppressive tumor microenvironment further hinders effective therapeutic responses.
Our BreakthroughEngineered probiotics as targeted cancer therapeutics
Deliver therapeutic agents directly to tumors
Our engineered microbes act as precision drug carriers, producing and releasing anticancer molecules mostly in the tumor microenvironment, minimizing off-target toxicity.
Act as intelligent biosensors
Engineered to detect specific tumor signals, our probiotics can dynamically adjust their therapeutic output, responding in real-time to the evolving cancer landscape.
Boost the efficacy of existing therapies
Acting as adjuvants, our engineered probiotics enhance the effectiveness of cancer treatments such as immune checkpoint inhibitors and chemotherapy, optimizing therapeutic outcomes.
Enhance the immune response
These probiotics can stimulate immune cells, reshape the tumor microenvironment.
Combining direct drug delivery and immune system modulation, our aim is to increase treatment efficacy while significantly reducing side effects.
By integrating synthetic biology with oncology, we are not just treating cancer—we are changing the way cancer is fought, turning natural microbes into precision-guided allies in the battle against this devastating disease.
Key BenefitsMaking cancer treatment more effective and targeted
Our platform is designed to adapt to changes in the tumor environment and overcome cancer’s resistance to treatment.
A multi-pronged approach
Our solution combines multiple functions in a single formulation, making treatment more efficient and effective.
Focusing on major cancer types
We are targeting breast and colorectal cancer—two of the three most common cancer types. While significant progress has been made in treating these diseases, major challenges remain.
Targeted therapy for better outcomes
We block specific cancer-promoting proteins and pathways, weakening the tumor while boosting body’s natural defenses.
Boosting standard cancer treatments
Our therapy enhances the effects of first-line therapy by helping immune cells and cancer-fighting drugs reach the tumor more effectively.
Treating both primary tumors and metastases
Removing the primary tumor is the first goal of any cancer treatment, but the real challenge is stopping the spread. Our therapy uses a live biotherapeutic product (LBP) that helps break down the tumor’s protective barrier, making it easier to eliminate both the primary tumor and its metastases.
Preventing cancer from coming back
Cancer recurrence is a major cause of death, and there’s no simple solution. Each type of cancer requires a different approach, placing a heavy burden on patients, families, and healthcare systems. Our solution is designed to prevent recurrence in a way that is safe, effective, and affordable.
